IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer letters"
DOI: 10.1016/j.canlet.2018.06.038
Abstract: Thyroid carcinomas (TCs) bearing BRAF mutations represent approximately 26-53% of human thyroid malignancies and, differently from melanomas, are poorly sensitive to BRAF inhibitors (BRAFi), and develop acquired resistance through activation of alternative signaling pathways. A… read more here.
Keywords: plx4032; braf; stat3 axis; il6 stat3 ... See more keywords
BRAF inhibitors and their immunological effects in malignant melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2044796
Abstract: ABSTRACT Introduction The treatment of cutaneous melanoma has been revolutionized by the development of small-molecule inhibitors targeting the MAPK pathway, including inhibitors of BRAF (BRAFi) and MEK (MEKi), and immune checkpoint blockade antibodies, occurring in… read more here.
Keywords: melanoma; inhibitors immunological; braf inhibitors; effects malignant ... See more keywords
MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.578
Abstract: Abstract BACKGROUND MEK and BRAF inhibitors are increasingly common treatments for pediatric nervous system tumors. While effective in blocking Ras/Raf/MEK/ERK pathway activation driving tumor progression, the side effect profile differs from traditional cytotoxic chemotherapies. Little… read more here.
Keywords: inhibitors bevacizumab; braf inhibitors; mek braf; grade ... See more keywords
Ophthalmic adverse effects of BRAF inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Ophthalmology"
DOI: 10.1177/11206721221132872
Abstract: To determine the frequency, characteristics, and clinical course of ophthalmic side effects associated with systemic BRAF inhibitor therapy. Medical records of patients taking BRAF inhibitors for the treatment of systemic malignances at Mayo Clinic, Rochester… read more here.
Keywords: adverse effects; therapy; side; ophthalmic adverse ... See more keywords
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021013502
Abstract: Hairy cell leukemia (HCL) responds very well to frontline chemotherapy with purine analogs (cladribine and pentostatine). However, about half of patients experience one or more relapses, which become progressively resistant to these myelotoxic and immunosuppressive… read more here.
Keywords: braf inhibitors; hairy cell; braf; cell leukemia ... See more keywords
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Translational Medicine"
DOI: 10.1186/s12967-020-02350-8
Abstract: Background Most mutations in melanoma affect one critical amino acid on BRAF gene, resulting in the V600E substitution. Patient management is often based on the use of specific inhibitors targeting this mutation. Methods DNA and… read more here.
Keywords: braf v600e; cell lines; braf; responsiveness braf ... See more keywords
Impact of immune checkpoint and BRAF inhibitors on the incidence of second primary malignancies (SPM) in melanoma.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.12061
Abstract: 12061Background: Prior studies have shown an increased risk of SPM in melanoma, however there is limited data on the incidence of SPM following the 2011 approvals of immune checkpoint (ipilimumab) ... read more here.
Keywords: immune checkpoint; checkpoint braf; spm melanoma; impact immune ... See more keywords
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.19836
Abstract: Identification of mutations in the gene encoding the serine/threonine-protein kinase, BRAF, and constitutive activation of the mitogen-activated protein kinase (MAPK) pathway in around 50% of malignant melanomas have led to the development and regulatory approval… read more here.
Keywords: inhibitors resistance; combination; resistance promise; combination treatments ... See more keywords
The multifaceted anti-cancer effects of BRAF-inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Oncotarget"
DOI: 10.18632/oncotarget.27304
Abstract: The BRAF gene is commonly involved in normal processes of cell growth and differentiation. The BRAF (V600E) mutation is found in several human cancer, causing an increase of cell proliferation due to a modification of… read more here.
Keywords: braf inhibitors; thyroid cancer; cancer; tumour microenvironment ... See more keywords
BRAF Inhibitors in Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14194863
Abstract: Simple Summary The identification of BRAF mutations in 1.5–3.5% of NSCLC patients represents a step forward towards new targeted agents for tackling NSCLC. The positive results and favourable safety profile observed with the combination of… read more here.
Keywords: cell; nsclc patients; role; braf ... See more keywords